|
|
| Line 1: |
Line 1: |
| '''Blastic plasmacytoid dendritic cell neoplasm''' (BPDCN) is a rare [[hematologic disease#Hematological malignancies|hematologic malignancy]]. It was initially regarded as a form of [[lymphocyte]]-derived cutaneous [[lymphoma]] and alternatively named CD4+CD56+ hematodermic tumor, blastic NK cell lymphoma,and agranular CD4+ NK cell leukemia.Later, however, the disease was determined to be a malignancy of [[plasmacytoid dendritic cell]]s rather than lymphocytes and therefore termed blastic plasmacytoid dendritic cell neoplasm. In 2016, the [[World Health Organization]] designated BPDCN to be in its own separate category within the [[Myeloid tissue|myeloid]] class of neoplasms. It is estimated that BPDCN constitutes 0.44% of all hematological malignancies.
| | Blastic Plasmacytoid Dendritic Cell Neoplasm |
|
| |
|
| Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy with features of [[cutaneous lymphoma]] (e.g. malignant plasmacytoid dendritic cell infiltrations into the skin to form single or multiple lesions) and/or leukemia (i.e. malignant plasmacytoid dendritic cells in blood and bone marrow). While commonly presenting with these clinical features, BPDCN, particularly in its more advanced stages, may also involve malignant plasmacytoid dendritic cell infiltrations in and thereby injury to the liver, spleen, [[lymph nodes]], [[central nervous system]], or other tissues. The neoplasm occurs in individuals of all ages but predominates in the elderly; in children, it afflicts males and females equally but in adults is far more common (~75% of cases) in males. | | Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the proliferation of plasmacytoid dendritic cells. It primarily affects the skin but can also involve the bone marrow, lymph nodes, and other organs. |
| =='''Symptoms'''==
| |
| Blastic plasmacytoid dendritic cell neoplasm occurs in children, including [[neonate]]s, but is more common in adults, particularly those between the ages 60-80. BPDCN usually (i.e. 61%to 90%of cases) presents with [[Skin lesions associated with|skin lesions]], i.e. nodules, [[tumors]], red or purple [[papule]]s, bruise-like patches, and/or [[ulcers]] that most often occur on the head, face, and upper torso.
| |
|
| |
|
| | ==Epidemiology== |
| | BPDCN is an uncommon disease, accounting for less than 1% of all hematologic malignancies. It predominantly affects older adults, with a median age of diagnosis around 60-70 years. There is a slight male predominance. |
|
| |
|
| The lesions are due to diffuse infiltrations of the skin by malignant pDC. In one large study, this presentation was accompanied by swollen [[lymph node]]s, usually in the neck, due to malignant pDC infiltrations (~50% of cases); enlarged liver (~16% of cases) and/or spleen (26% of cases), also due to malignant pDC infiltrations;increased levels of malignant [[pDC]] in blood (i.e. >2% of nucleated cells) (~40% of cases), bone marrow (~65% of cases) and [[cerebrospinal fluid]] (47% of childhood cases but less often detected in adult cases).
| | ==Pathophysiology== |
| | BPDCN arises from the malignant transformation of [[plasmacytoid dendritic cells]], which are a type of immune cell involved in the production of [[interferon]] and the activation of other immune cells. The exact cause of this transformation is not well understood, but genetic mutations and chromosomal abnormalities have been implicated. |
|
| |
|
| | ==Clinical Presentation== |
| | Patients with BPDCN often present with skin lesions, which may appear as bruise-like patches, nodules, or plaques. These lesions are typically purple or red and can occur anywhere on the body. In addition to skin involvement, patients may experience systemic symptoms such as fever, fatigue, and weight loss. |
|
| |
|
| More advanced or severe cases may present with extreme organ and/or lymph node enlargements, skin lesions in virtually any site, and clinical evidence of malignant pDC [[infiltrations]] in the breasts, eyes, kidneys, lungs, gastrointestinal tract, bone, sinuses, ears, or testes.<ref name="pmid28906324">{{cite journal | vauthors = Kim MJ, Nasr A, Kabir B, de Nanassy J, Tang K, Menzies-Toman D, Johnston D, El Demellawy D | title = Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Systematic Literature Review | journal = Journal of Pediatric Hematology/Oncology | volume = 39 | issue = 7 | pages = 528–537 | date = October 2017 | pmid = 28906324 | doi = 10.1097/MPH.0000000000000964 | url = }}</ref> About 10% of individuals with BPDCN present with a [[leukemia]]-like disease,i.e. they exhibit circulating malignant pDC, [[anemia]], [[thrombocytopenia]], and/or [[leukopenia]] due to extensive malignant pDC infiltrations in the bone marrow. A leukemic phase of the disease is a common feature of end stage and post-therapy relapsing BPDCN.
| |
| ==Diagnosis== | | ==Diagnosis== |
| BPDCN is suggested by a biopsy of skin lesions which reveals the infiltration by medium-sized blast (i.e. immature) cells into the [[dermis]] while sparing the epidermis. These cells exhibit irregular [[Cell nucleus|nuclei]], fine [[chromatin]], and at least one small [[nucleolus]]. | | The diagnosis of BPDCN is based on a combination of clinical, histopathological, and immunophenotypic findings. A skin biopsy is often performed to examine the characteristic infiltration of plasmacytoid dendritic cells. Immunohistochemistry is used to identify specific markers such as CD4, CD56, and CD123, which are typically expressed in BPDCN cells. |
|
| |
|
| | ==Treatment== |
| | Treatment options for BPDCN are limited and often involve a combination of chemotherapy and targeted therapies. The most common initial treatment is a chemotherapy regimen similar to those used for acute lymphoblastic leukemia. Recently, targeted therapies such as tagraxofusp, a CD123-directed cytotoxin, have shown promise in treating BPDCN. |
|
| |
|
| Such blast cells may also be observed in the circulation, bone marrow, or other tissues and suggest BPDCN. However, the diagnosis of this disease requires determination that these cells are pDC blast cells rather than AML, [[Lymphoma|T-cell lymphoblastic lymphoma]] (TCLL), or [[aggressive NK-cell leukemia]] (NKL) blast cells. Various studies have offered similar but not identical criteria to make this determination.
| | ==Prognosis== |
| | The prognosis for BPDCN is generally poor, with a median survival of less than two years. The aggressive nature of the disease and its tendency to relapse contribute to the challenging management of BPDCN. Early diagnosis and treatment are crucial for improving outcomes. |
|
| |
|
| | ==Research and Future Directions== |
| | Ongoing research is focused on understanding the molecular mechanisms underlying BPDCN and developing more effective therapies. Clinical trials are exploring new targeted agents and immunotherapies that may offer hope for patients with this challenging disease. |
|
| |
|
| All studies agree that pDC should have a typical plasmacytoid [[Morphology (biology)|morphology]] and express a particular profile of marker proteins as detected by [[immunoassay]] and/or [[flow cytometry]]. However, the studies disagree on which marker proteins to profile. One study's profile assayed '''1)''' [[CD4]], [[CD56]], CD123 (i.e. [[Interleukin-3 receptor]], and [[TLC1]], which are expressed on 80-100% of pDC but uncommon on AML, TCLL, or NKL blasts); '''2)''' [[CD2AP]] and [[CLEC4C]] which are unique to pDC; and '''3)''' [[myeloperoxidase]], [[lysozyme]], [[CD34]], [[CD14]], [[CD11c]], and [[CD163]] which are unique to AML, TCLL, or NKL blasts.<ref name="pmid27913457">{{cite journal | vauthors = Sullivan JM, Rizzieri DA | title = Treatment of blastic plasmacytoid dendritic cell neoplasm | journal = Hematology. American Society of Hematology. Education Program | volume = 2016 | issue = 1 | pages = 16–23 | date = December 2016 | pmid = 27913457 | pmc = 6142460 | doi = 10.1182/asheducation-2016.1.16 | url = }}</ref> Two other studies recommended assaying somewhat different sets of marker proteins.<ref name="pmid29760611">{{cite journal | vauthors = Owczarczyk-Saczonek A, Sokołowska-Wojdyło M, Olszewska B, Malek M, Znajewska-Pander A, Kowalczyk A, Biernat W, Poniatowska-Broniek G, Knopińska-Posłuszny W, Kozielec Z, Nowicki R, Placek W | title = Clinicopathologic retrospective analysis of blastic plasmacytoid dendritic cell neoplasms | journal = Postepy Dermatologii I Alergologii | volume = 35 | issue = 2 | pages = 128–138 | date = April 2018 | pmid = 29760611 | pmc = 5949541 | doi = 10.5114/ada.2017.72269 | url = }}</ref><ref name="pmid29705980" />
| | ==See Also== |
| =='''Treatment'''==
| | * [[Hematologic malignancy]] |
| Agraxofusp-erzs (Elzonris) is a CD123-directed cytotoxin approved for the treatment of blastic plasmacytoid dendritic (BPDCN) in adults and in pediatric patients 2 years and older.
| | * [[Plasmacytoid dendritic cell]] |
| ==Prognosis==
| | * [[Interferon]] |
| Due to the high rates of recurrence following initial therapy and the short overall survival times of individuals with BPDCN, prognosis of the disease is poor. However, further study of treatment regimens that include intrathecal chemotherapy and hematological stem cell transplantation in initial treatment regimens (see previous section) and newer non-chemotherapeutic drug treatments (see next section) may improve this situation.<ref name="pmid29455234" />
| | |
| | {{Hematology}} |
| | {{Lymphoma}} |
|
| |
|
| {{rarediseases}}
| | [[Category:Hematologic neoplasms]] |
| <references />
| | [[Category:Rare diseases]] |
| | [[Category:Dermatology]] |
Blastic Plasmacytoid Dendritic Cell Neoplasm
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the proliferation of plasmacytoid dendritic cells. It primarily affects the skin but can also involve the bone marrow, lymph nodes, and other organs.
Epidemiology[edit]
BPDCN is an uncommon disease, accounting for less than 1% of all hematologic malignancies. It predominantly affects older adults, with a median age of diagnosis around 60-70 years. There is a slight male predominance.
Pathophysiology[edit]
BPDCN arises from the malignant transformation of plasmacytoid dendritic cells, which are a type of immune cell involved in the production of interferon and the activation of other immune cells. The exact cause of this transformation is not well understood, but genetic mutations and chromosomal abnormalities have been implicated.
Clinical Presentation[edit]
Patients with BPDCN often present with skin lesions, which may appear as bruise-like patches, nodules, or plaques. These lesions are typically purple or red and can occur anywhere on the body. In addition to skin involvement, patients may experience systemic symptoms such as fever, fatigue, and weight loss.
Diagnosis[edit]
The diagnosis of BPDCN is based on a combination of clinical, histopathological, and immunophenotypic findings. A skin biopsy is often performed to examine the characteristic infiltration of plasmacytoid dendritic cells. Immunohistochemistry is used to identify specific markers such as CD4, CD56, and CD123, which are typically expressed in BPDCN cells.
Treatment[edit]
Treatment options for BPDCN are limited and often involve a combination of chemotherapy and targeted therapies. The most common initial treatment is a chemotherapy regimen similar to those used for acute lymphoblastic leukemia. Recently, targeted therapies such as tagraxofusp, a CD123-directed cytotoxin, have shown promise in treating BPDCN.
Prognosis[edit]
The prognosis for BPDCN is generally poor, with a median survival of less than two years. The aggressive nature of the disease and its tendency to relapse contribute to the challenging management of BPDCN. Early diagnosis and treatment are crucial for improving outcomes.
Research and Future Directions[edit]
Ongoing research is focused on understanding the molecular mechanisms underlying BPDCN and developing more effective therapies. Clinical trials are exploring new targeted agents and immunotherapies that may offer hope for patients with this challenging disease.
See Also[edit]
| Lymphomas |
| General | |
| Types | |
| Diagnosis and Treatment | |
| Related | |
This lymphoma-related article is a stub.
|
